Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1)

被引：37

作者：

Matsunaga, Seita ^{[1
]}

Asano, Takeshi ^{[1
]}

Tsutsuda-Asano, Arisa ^{[1
]}

Fukunaga, Yoshitaka ^{[1
]}

机构：

[1] Chiba Hokusoh Hosp, Dept Pediat, Nippon Med Sch, Chiba 2701894, Japan

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2006年 / 58卷 / 03期

关键词：

K562; doxorubicin-resistant; multi-drug resistance protein 1; indomethacin; promoter;

D O I：

10.1007/s00280-005-0162-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Drug resistance continues to be a serious problem in cancer therapy. We investigated whether indomethacin, which inhibited cyclooxygenases, would overcome doxorubicin resistance in K562/ADR leukemia cells. Indomethacin at 10 mu M increased the cytotoxicity of doxorubicin, as well as vincristine in K562/ADR. Both multi-drug resistant protein1 (MRP1) and P-glycoprotein were overexpressed in K562/ADR cells when compared with K562 parent cells (K562/P). Expression of MRP1 mRNA and protein, but not P-glycoprotein, was significantly decreased in K562/ADR cells after indomethacin treatment. Indomethacin treatment increased 5(6)-carboxyfluorescein diacetate (CFDA) efflux, as well as decreased accumulation in K562/ADR cells. The activity of the MRP1 promoter decreased after indomethacin treatment in Hela cells. These data strongly suggest that the cyclooxygenase inhibitor, indomethacin, increased the cytotoxicity of doxorubicin with decreasing expression of MRP1 through inhibition of MRP1 promoter activity.

引用

页码：348 / 353

页数：6

共 17 条

[1] Transfection of human topoisomerase II alpha into etoposide-resistant cells: Transient increase in sensitivity followed by down-regulation of the endogenous gene [J].

Asano, T ;

An, TH ;

Mayes, J ;

Zwelling, LA ;

Kleinerman, ES .

BIOCHEMICAL JOURNAL, 1996, 319 :307-313

[2]

ASANO T, 2003, JPN J PEDIAT HEMATOL, V17, P348

[3]

BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096

[4] Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein [J].

Draper, MP ;

Martell, RL ;

Levy, SB .

BRITISH JOURNAL OF CANCER, 1997, 75 (06) :810-815

[5] DETECTION OF P-GLYCOPROTEIN IN MULTIDRUG-RESISTANT CELL-LINES BY MONOCLONAL-ANTIBODIES [J].

KARTNER, N ;

EVERNDENPORELLE, D ;

BRADLEY, G ;

LING, V .

NATURE, 1985, 316 (6031) :820-823

[6]

KOLK DM, 2002, LEUKEMIA LYMPHOMA, V43, P685

[7]

Kundu N, 2002, CANCER RES, V62, P2343

[8] Identification of DNA-protein interactions in the 5′ flanking and 5′ untranslated regions of the human multidrug resistance protein (MRP1) gene:: Evaluation of a putative antioxidant response element/AP-1 binding site [J].

Kurz, EU ;

Cole, SPC ;

Deeley, RG .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 285 (04) :981-990

[9] Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia [J].

Legrand, O ;

Simonin, G ;

Beauchamp-Nicoud, A ;

Zittoun, R ;

Marie, JP .

BLOOD, 1999, 94 (03) :1046-1056

[10] MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models [J].

Mahon, FX ;

Belloc, F ;

Lagarde, V ;

Chollet, C ;

Moreau-Gaudry, F ;

Reiffers, J ;

Goldman, JM ;

Melo, JV .

BLOOD, 2003, 101 (06) :2368-2373

← 1 2 →